Breaking News Instant updates and real-time market news.

RETA

Reata Pharmaceuticals

$27.44

1.9 (7.44%)

09:16
10/06/16
10/06
09:16
10/06/16
09:16

Reata Pharmaceuticals enrolls first patient in Phase 3 CATALYST trial

Reata Pharmaceuticals announced that it has enrolled the first patient into its Phase 3 CATALYST trial to evaluate the efficacy and safety of bardoxolone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension.

RETA Reata Pharmaceuticals
$27.44

1.9 (7.44%)

06/20/16
COWN
06/20/16
INITIATION
Target $22
COWN
Outperform
Reata Pharmaceuticals initiated with an Outperform at Cowen
Cowen initiated Reata Pharmaceuticals with an Outperform based on the company's potential for clinical and commercial success of its lead candidate bardoxolone in PAH-CTD, which has data in 1H18, as well as significant value in other indications. Cowen has a $22 price target on Reata Pharmaceuticals shares.
06/20/16
SBSH
06/20/16
INITIATION
Target $32
SBSH
Buy
Reata Pharmaceuticals initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz started Reata Pharmaceuticals with a Buy rating and $32 price target. The analyst sees "considerable room" for the company's lead drug, Bardoxolone Methyl, to operate in the pulmonary arterial hypertension market.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.